Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

2(40.0%)

Phase 2

1(20.0%)

Phase 1

1(20.0%)

Phase 4

1(20.0%)

5Total

Phase 3(2)

Phase 2(1)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05750511Unknown

Multicenter Tissue Registry in Melanoma

Role: lead

NCT00204529Phase 3Completed

Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB

Role: collaborator

NCT00122473Phase 1Completed

Imatinib in Dermatofibrosarcoma Protuberans (DFSP)

Role: lead

NCT00623402Phase 2Completed

Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma

Role: collaborator

NCT00226473Phase 4Unknown

Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma

Role: lead

NCT00226408Phase 3Unknown

Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

Role: lead

All 6 trials loaded